Miami, FL – November 2024 – Global Stem Cells Group (GSCG), a recognized leader in
regenerative medicine and cellular therapies, is pleased to announce the upcoming launch of a
new clinic, set to open on November 23, 2024, in Dubai. This strategic initiative represents a
significant expansion of GSCG’s global footprint, as it seeks to offer advanced regenerative
solutions to new and vital markets.
The new clinic, located at the Hyatt Hotel in Jumeirah, is poised to become a hub for cutting-
edge regenerative treatments. The clinic aims to provide a comprehensive range of therapies,
including stem cell treatments, exosome applications, natural killer (NK) cell therapies, aesthetic
procedures, and interventions focused on promoting longevity. GSCG aspires to enhance
patient access to these innovative treatments across the region.
ISSCA to Host Conference in Dubai on November 22 and 23 Using Global Stem Cells Group’s Facilities
The International Society for Stem Cell Application (ISSCA), the educational division of Global
Stem Cells Group, will host a two-day conference as part of its 2.0 series, featuring the latest
advancements in regenerative medicine. Scheduled for November 22 and 23, this event will
include theoretical sessions on the first day at the Le Méridien Dubai Hotel & Conference
Centre, followed by practical hands-on demonstrations at the new Global Stem Cells Group
clinic on the second day. The hands-on portion, taking place on November 23, will provide
attendees with the opportunity to apply their knowledge directly in a clinical setting, under the
guidance of top experts in regenerative medicine.
The conference will feature top speakers in the field, who will share their insights and
advancements in various areas of regenerative medicine. Topics covered at the conference
include NK Cells, allogeneic PRP, human placenta, nanorevive, progenicell, peptides, CAR-T
cells, 3D bioprinting, biohacking, Wharton’s jelly, young donor plasma, and exosomes MSC.
This comprehensive agenda is designed to provide in-depth knowledge on cutting-edge
therapies such as peptides, NK cells, donor-derived stem cells, exosomes, and other advanced
treatment modalities. ISSCA’s 2.0 series seeks to equip medical professionals with updated
knowledge and skills in the most recent developments in regenerative therapies.
“We hope that this new clinic in Dubai will establish itself as a center of excellence, not only for
treatment but also for continuous education,” said Benito Novas, founder and CEO of Global
Stem Cells Group. “We believe this initiative will empower both doctors and patients by
providing access to innovative regenerative solutions. We expect it to be a meaningful milestone
in expanding our mission to deliver transformative medical therapies globally.”
A Distribution Hub for Cellgenic Products in the Middle East
The Dubai clinic is expected to serve as a key distribution center for Cellgenic products,
including the registered lyophilized exosome product. The goal is to enable efficient local and
international distribution, facilitating access to advanced regenerative products throughout the
region.
The Growing Global Demand for Regenerative Medicine
The regenerative medicine sector continues to grow, driven by increasing demand for
treatments that support healing, promote longevity, and improve overall health. With over 15
years of experience, Global Stem Cells Group aims to contribute meaningfully to this evolving
field by offering comprehensive solutions designed to address complex conditions and enhance
patient quality of life.
The Dubai clinic is expected to offer an extensive range of therapies, including:
● Mesenchymal Stem Cell (MSC) therapies, believed to promote tissue repair and overall
health.
● Exosome therapies, anticipated to support aesthetic enhancements and orthopedic
recovery.
● Natural Killer (NK) cell therapies, which aim to enhance immune system function.
● Anti-aging and longevity treatments, combining cellular therapies with therapeutic
peptides.
● Platelet-Rich Plasma (PRP) injections, expected to accelerate healing and rejuvenation.
● Specialized therapeutic peptides, aimed at addressing specific health conditions.
Dubai as a Promising Destination for Medical Tourism
Dubai’s international reputation as a premier destination positions it well to attract patients
seeking advanced regenerative treatments. GSCG anticipates that the new clinic will draw
interest from medical tourists worldwide, offering tailored treatment plans for conditions such as
autoimmune disorders, orthopedic injuries, and skin rejuvenation. The combination of innovative
medical solutions and a patient-centric approach is expected to make the Dubai clinic a vital
part of the city’s emerging status as a hub for advanced healthcare.
About Global Stem Cells Group
Founded by Benito Novas, Global Stem Cells Group seeks to advance the field of regenerative
medicine globally. With a robust presence across continents, the organization provides both
treatments and educational programs aimed at empowering doctors, researchers, and patients.
Through ISSCA, GSCG conducts specialized training, certification, and hands-on workshops
designed to promote best practices in the application of cellular therapies.
For more information about the Dubai clinic opening, ISSCA training event, or Global Stem Cells
Group, please visit the Global Stem Cells Group website.
Global Stem Cells Group is a publicly traded company operating under the symbol RMTG.
https://finance.yahoo.com/quote/RMTG/
To learn more about Global Stem Cells Group, Inc.’s companies, visit our website
www.stemcellsgroup.com or call +1 305 560 5331.
Safe Harbor Statement: Statements in this news release may be “forward-looking statements”.
Forward-looking statements include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions, or any other information relating to our
future activities or other future events or conditions. These statements are based on current
expectations, estimates, and projections about our business based partly on assumptions made
by management. These statements are not guarantees of future performance and involve risks,
uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and
results may and are likely to differ materially from what is expressed or forecasted in forward-
looking statements due to numerous factors. Any forward-looking statements speak only as of
the date of this news release, and The Global Stem Cells Group undertakes no obligation to
update any forward-looking statement to reflect events or circumstances after the date of this
news release. This press release does not constitute a public offer of any securities for sale.
Any securities offered privately will not be or have not been registered under the Act and may
not be offered or sold in the United States absent registration or an applicable exemption from
registration requirements.
